The $1 million, two-month project is a collaboration of 454 Life Sciences and the BCM Human Genome Sequencing Center (HGSC), said Dr. Richard Gibbs, director of the HGSC and a scientific advisor to the Connecticut-based company.
An international team of researchers have been awarded more than ?2 million to study the genetic causes of dwarfism in a bid to develop future treatments.
Mass-media advertising can encourage more people experiencing stroke symptoms to go to the hospital more quickly, according to a study published in Stroke: Journal of the American Heart Association.
The majority of doctors in North Carolina do not probe for signs of postpartum depression in new mothers, according to a survey conducted by researchers at the University of North Carolina at Chapel Hill.
Almost two-thirds (65%) of hip fracture patients aged 65 and older had surgery on the day they were admitted to hospital or the next day in 2005?2006, but new indicators published by the Canadian Institute for Health Information (CIHI) show that some patients have longer waits.
HopeLab validated the benefits of their cancer-fighting video game by conducting a randomized, controlled trial with 375 male and female cancer patients aged 13 – 29, enrolled at 34 medical centers in the U.S., Canada and Australia.
CIGNA HealthCare is teaming up with the non-profit organization HopeLab to deliver innovative interventions that improve the health and quality of life of young people with chronic illnesses.
In response to the CDC health alert about an outbreak of Acanthamoeba keratitis, a rare but serious eye infection, the American Academy of Ophthalmology is offering advice to all contact lens wearers to reduce their risk of eye infections.
Pfizer Inc announced that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has recommended Champix (varenicline) for use on the National Health Service for adult smokers who have expressed a desire to quit.
A new study showing a reduction in the toxic side effects of ROS-generating chemotherapies with concurrent antioxidant supplementation will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) that takes place June 1-5 at McCormick Place in Chicago.